The calculus of cures

New England Journal of Medicine

Volumn 370, Issue 16, 2014, Pages 1473-1475

  Kocher, Robert ^a,b   Roberts, Bryan ^a  

^a Venrock   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG MARKETING; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECONOMIC EVALUATION; FUNDING; HEALTH CARE POLICY; HUMAN; PRIORITY JOURNAL; RARE DISEASE; SHORT SURVEY;

DRUG APPROVAL; DRUG COSTS; DRUG DISCOVERY; DRUG EVALUATION; DRUG INDUSTRY; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84898605151     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1400868     Document Type: Article

References (4)

1. New drugs at FDA: CDER's new molecular entities and new therapeutic biological products of 2014. Silver Spring, MD: Food and Drug Administration (http://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/default.htm) .
2. Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy 2011;100:4-17.
3. Kantarjian HM, Fojo T, Mathiesen M, Zwelling LA. Cancer drugs in the United States: justum pretium - the just price. J Clin Oncol 2013;31:3600-4.
4. Duijnhoven RG, Straus SM, Raine JM, de Boer A, Hoes AW, De Bruin ML. The number of patients studied prior to approval of new medicines: a database analysis. PLoS Med 2013;10(3):e1001407.